Breast Cancer | Specialty

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

December 17th 2014

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

Dr. Chlebowski on How Weight Loss Improves TNBC Survival

December 16th 2014

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Gene Test Predicts DCIS Recurrence Risk

December 12th 2014

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk

Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention

December 12th 2014

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1

December 12th 2014

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer

Upfront Fulvestrant Improves Survival Over Anastrozole in HR-Positive MBC

December 12th 2014

Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer

Dr. Nanda On Pembrolizumab Potential for TNBC

December 12th 2014

Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of Chicago, discusses the potential of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer (TNBC). A recent small-scale trial showed treatment response for 18.5% of patients with PD-L1 positive TNBC.

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype

December 12th 2014

Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen

December 11th 2014

Chemo Adds No Benefit to Bisphosphonate In Older Breast Cancer Patients

December 11th 2014

Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.

Tamoxifen's Sustained Power to Prevent Breast Cancer in High-Risk Women Confirmed

December 11th 2014

Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.

Ovarian Suppression Emerges as "Practice-Changing" Option for Younger, Premenopausal Breast Cancer Patients

December 11th 2014

Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

TNBC Subtype Responds Favorably to Neoadjuvant Bevacizumab

December 11th 2014

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Dr. Francis on the Benefits of Ovarian Suppression for Younger Women

December 11th 2014

Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial

December 11th 2014

Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.

Dr. Weigert on Cancer Screening for Women With Dense Breasts

December 10th 2014

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

December 10th 2014

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Pembrolizumab Elicits Antitumor Responses in TNBC

December 10th 2014

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC

December 10th 2014

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.